Analysis of cytogenetic aberrations in sporadic vestibular schwannoma by comparative genomic hybridization
Tóm tắt
Vestibular schwannomas (VS) are benign tumors of the nervous system that are usually sporadic but also occur in the inherited disorder neurofibromatosis type 2 (NF2). The NF2 gene is a tumor suppressor gene located on chromosome 22. Loss of the NF2 protein product, Merlin, is universal in both sporadic and NF2-related schwannomas and the loss or mutation of the gene is the only established causative event underlying schwannoma formation. Comparative genomic hybridization (CGH) was used to screen 20 sporadic VS to identify additional chromosomal regions that may harbor genes involved in VS-tumorigenesis. The most common change were losses on chromosome 22q. Additionally, losses were observed on chromosome 9p indicating a possible participation of the CDKN2A tumor suppressor gene in the genesis of VS. Gains were observed on 17q, 19p and 19q, which have been reported before in malignant peripheral nerve sheath tumors that are associated with neurofibromatosis type 1. Importantly, high level amplifications have been observed on 16p and 16q as well as on 9q, suggesting the possible involvement of several oncogenes in the tumorigenesis of VS. Our data suggest the involvement of various oncogenes and tumor suppressor genes might play a role in the genesis of the vestibular schwannomas apart from the inactivation of the NF2 gene.
Tài liệu tham khảo
Charabi S, Tos M, Thomsen J, Charabi B, Mantoni M (2000) Vestibular schwannoma growth: the continuing controversy. Laryngoscope 110:1720–1725
Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, NewtonV Strachan T, Ramsden R, Harris R (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841–846
Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Maher ER (1994) Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma. Hum Mol Genet 3:347–350
Telenius H, Carter NP, Bebb CE, Nordenskjold M, Ponder BA, Tunnacliffe A (1992) Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics 13:718–725
Kalliomeni A, Kalliomeni OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D (1994) Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10:231–243
du Manoir S, Speicher MR, Joos S, Schrock E, Popp S, Dohner H, Kovacs G, Robert-Nicoud M, Lichter P, Cremer T (1993) Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet 90:590–610
Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Xuan-K Hoang, Demczuk S, Desmaze Z, Plougastel B (1993) Alteration in a new gene encoding a putative membrane-organizing causes neuro-fibromatosis type 2. Nature 363:515–521
Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K (1993) A novel moezin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor supressor gene. Cell 72:791–800
Warren C, James LA, Ramsden RT, Wallace A, Baser ME, Varley JM, Evans DG (2003) Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridization. J Med Genet 40:802–806
Ikeda T, Hashimoto S, Fukushige S, Ohmori H, Horii A (2005) Comparative genomic hybridization and mutation analyses of sporadic schwannomas. J Neurooncol 72:225–230
Antinheimo J, Sallinen SL, Sallinen P, Haapasalo H, Helin H, Horelli-Kuitunen N, Wessman M, Sainio M, Jääskeläinen J, Carpén O (2000) Genetic aberrations in sporadic and neurofibromatosis 2 (NF2)-associated schwannomas studied by comparative genomic hybridization (CGH). Acta Neurochir 142:1099–1104
Serano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707
Merlo GR, Cropp CS, Callahan R, Takahashi T (1991) Detection of loss of heterozygosity in tumor DNA samples by PCR. Biotechniques 11:166–171
Berner JM, Sørlie T, Mertens F, Henriksen J, Saeter G, Mandahl N, Brøgger A, Myklebost O, Lothe RA (1999) Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway. Genes Chromosomes Cancer 26:151–160
Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, Han ZY, Chareyre F, Niwa-Kawakita M, Black PM, Carroll RS, Giovannini M (2008) Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol 18:62–70
Rylova SN, Amalfitano A, Persaud-Sawin DA, Guo WX, Chang J, Jansen PJ, Proia AD, Boustany RM (2002) The CLN3 gene is a novel molecular target for cancer drug discovery. Cancer Res 62:801–808
Scoles DR, Yong WH, Qin Y, Wawrowsky K, Pulst SM (2006) Schwannomin inhibits tumorigenesis through direct interaction with the eucaryotic initiation factor subunit c (elF3c). Hum Mol Genet 15:1059–1070
Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, McKeown C, Sanders DS, Maher ER (1999) Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 8:607–610
Silye R, Karayiannakis AJ, Syrigos KN, Poole S, van Noorden S, Batchelor W, Regele H, Sega W, Boesmueller H, Krausz T, Pignatelli M (1998) E-cadherin/catenin complex in benign and malignant melanocytic lesions. J Pathol 186:350–355
Hasegawa M, Muramatsu N, Tohma Y, Fukaya K, Fujisawa H, Hayashi Y, Tachibana O, Kida S, Yamashita J, Saito K (2002) Expression of E-cadherin–catenin complex in human benign schwannomas. Histol Histopathol 17:39–44
Schmidt H, Taubert H, Würl P, Bache M, Bartel F, Holzhausen HJ, Hinze R (2001) Cytogenetic characterization of six malignant peripheral nerve sheath tumors: comparison of karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 128:14–23
Woltuis RM, Bos JL (1999) Ras caught in another affair: the exchange factors for Ral. Curr Opin Genet Dev 9:112–117
González-García A, Pritchard CA, Paterson HF, Mavria G, Stamp G, Marshall CJ (2005) RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 7:219–226
Gill S, Stratton MR, Patterson H, Spurr NK, Fisher C, Gusterson BA, Cooper CS (1991) Detection of transforming genes by transfection of DNA from primary soft-tissue tumors. Oncogene 6:1651–1656
Bustelo XR (2000) Regulatory and signaling properties of the Vav family. Mol Cell Biol 20:1461–1477
Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, Bommert K, Mechta-Grigoriou F, Stein H, Dörken B, Scheidereit C (2002) Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 21:4104–4113
Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR (1992) AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89:9267–9271
Han EK, Begemann M, Sgambato A, Soh JW, Doki Y, Xing WQ, Liu W, Weinstein IB (1996) Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ 7:699–710
Koga T, Iwasaki H, Ishiguro M, Matsuzaki A, Kikuchi M (2002) Losses in chromosomes 17, 19, and 22q in neurofibromatosis type 1 and sporadic neurofibromas: a comparative genomic hybridization analysis. Cancer Genet Cytogenet 136:113–120
Light JP, Roland JT Jr, Fishman A, Miller DC, Cohen NL (2001) Atypical and low-grade malignant vestibular schwannomas: clinical implications of proliferative activity. Otol Neurotol 22:922–927
Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN, Bates SE (1997) Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 89:1505–1515
Eccles SA (2001) The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 6:393–406
Clark JJ, Provenzano M, Diggelmann HR, Xu N, Hansen SS, Hansen MR (2008) The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol Neurotol 29:846–853